Overexpression of Raf-1 and ERK1/2 in sacral chordoma and association with tumor recurrence

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 1, 2015, Pages 608-614

  Zhang, Kai ^a   Chen, Hao ^a   Zhang, Bin ^a   Sun, Jiajia ^a   Lu, Jian ^a   Chen, Kangwu ^a   Yang, Huilin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

ERK1 2; Prognosis; Raf 1; Recurrence; Sacral chordoma

Indexed keywords

MAPK1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RAF PROTEIN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; BIOSYNTHESIS; CHORDOMA; DISEASE FREE SURVIVAL; ENZYMOLOGY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SACRUM; SPINE TUMOR; TUMOR RECURRENCE; UPREGULATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOMARKERS, TUMOR; CHORDOMA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-RAF; SACRUM; SPINAL NEOPLASMS; UP-REGULATION; YOUNG ADULT;

EID: 84923082158     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Tirabosco R, Mangham DC, Rosenberg AE, Vujovic S, Bousdras K, Pizzolitto S, De Maglio G, den Bakker MA, Di Francesco L, Kalil RK, Athanasou NA, O'Donnell P, McCarthy EF and Flanagan AM. Brachyury expression in extra-axial skeletal and soft tissue chordomas: a marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue. Am J Surg Pathol 2008; 32: 572-580.
2. Scheil-Bertram S, Kappler R, von Baer A, Hartwig E, Sarkar M, Serra M, Bruderlein S, Westhoff B, Melzner I, Bassaly B, Herms J, Hugo HH, Schulte M and Moller P. Molecular profiling of chordoma. Int J Oncol 2014; 44: 1041-1055.
3. Chugh R, Tawbi H, Lucas DR, Biermann JS, Schuetze SM and Baker LH. Chordoma: the nonsarcoma primary bone tumor. Oncologist 2007; 12: 1344-1350.
4. Li X, Ji Z, Ma Y, Qiu X, Fan Q and Ma B. Expression of hypoxia-inducible factor-1alpha, vascular endothelial growth factor and matrix metalloproteinase-2 in sacral chordomas. Oncol Lett 2012; 3: 1268-1274.
5. Kayani B, Hanna SA, Sewell MD, Saifuddin A, Molloy S and Briggs TW. A review of the surgical management of sacral chordoma. Eur J Surg Oncol 2014; 40: 1412-1420.
6. Sciubba DM, Cheng JJ, Petteys RJ, Weber KL, Frassica DA and Gokaslan ZL. Chordoma of the sacrum and vertebral bodies. J Am Acad Orthop Surg 2009; 17: 708-717.
7. Hanna SA, Aston WJ, Briggs TW, Cannon SR and Saifuddin A. Sacral chordoma: can local recurrence after sacrectomy be predicted? Clin Orthop Relat Res 2008; 466: 2217-2223.
8. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F and Libra M. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006; 46: 249-279.
9. Sippel RS and Chen H. Activation of the ras/raf-1 signal transduction pathway in carcinoid tumor cells results in morphologic transdifferentiation. Surgery 2002; 132: 1035-1039.
10. Chen L, Shi Y, Jiang CY, Wei LX, Wang YL and Dai GH. Expression and prognostic role of pan-Ras, Raf-1, pMEK1 and pERK1/2 in patients with hepatocellular carcinoma. Eur J Surg Oncol 2011; 37: 513-520.
11. Qiu ZX, Wang L, Han J, Liu D, Huang W, Altaf K, Qiu XS, Javed MA, Zheng J, Chen BJ and Li WM. Prognostic impact of Raf-1 and p-Raf-1 expressions for poor survival rate in non-small cell lung cancer. Cancer Sci 2012; 103: 1774-1779.
12. Hagemann C, Gloger J, Anacker J, Said HM, Gerngras S, Kuhnel S, Meyer C, Rapp UR, Kammerer U, Vordermark D, Flentje M, Roosen K and Vince GH. RAF expression in human astrocytic tumors. Int J Mol Med 2009; 23: 17-31.
13. Cekanova M, Majidy M, Masi T, Al-Wadei HA and Schuller HM. Overexpressed Raf-1 and phosphorylated cyclic adenosine 3'-5'-monophosphatate response element-binding protein are early markers for lung adenocarcinoma. Cancer 2007; 109: 1164-1173.
14. Daum G, Eisenmann-Tappe I, Fries HW, Troppmair J and Rapp UR. The ins and outs of Raf kinases. Trends Biochem Sci 1994; 19: 474-480.
15. Bartholomeusz C, Gonzalez-Angulo AM, Liu P, Hayashi N, Lluch A, Ferrer-Lozano J and Hortobagyi GN. High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients. Oncologist 2012; 17: 766-774.
16. Levidou G, Saetta AA, Gigelou F, Karlou M, Papanastasiou P, Stamatelli A, Kavantzas N, Michalopoulos NV, Agrogiannis G, Patsouris E and Korkolopoulou P. ERK/pERK expression and B-raf mutations in colon adenocarcinomas: correlation with clinicopathological characteristics. World J Surg Oncol 2012; 10: 47.
17. Mukherjee R, Bartlett JM, Krishna NS, Underwood MA and Edwards J. Raf-1 expression may influence progression to androgen insensitive prostate cancer. Prostate 2005; 64: 101-107.
18. McMaster ML, Goldstein AM, Bromley CM, Ishibe N and Parry DM. Chordoma: incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control 2001; 12: 1-11.
19. Maclean FM, Soo MY and Ng T. Chordoma: radiological-pathological correlation. Australas Radiol 2005; 49: 261-268.
20. Yang H, Zhu L, Ebraheim NA, Liu X, Castillo S, Tang T, Liu J and Cui H. Analysis of risk factors for recurrence after the resection of sacral chordoma combined with embolization. Spine J 2009; 9: 972-980.
21. Chen KW, Yang HL, Lu J, Liu JY and Chen XQ. Prognostic factors of sacral chordoma after surgical therapy: a study of 36 patients. Spinal Cord 2010; 48: 166-171.
22. Leicht DT, Balan V, Kaplun A, Singh-Gupta V, Kaplun L, Dobson M and Tzivion G. Raf kinases: function, regulation and role in human cancer. Biochim Biophys Acta 2007; 1773: 1196-1212.
23. Cui X, Li S, Li T, Pang X, Zhang S, Jin J, Hu J, Liu C, Yang L, Peng H, Jiang J, Liang W, Suo J, Li F and Chen Y. Significance of elevated ERK expression and its positive correlation with EGFR in Kazakh patients with esophageal squamous cell carcinoma. Int J Clin Exp Pathol 2014; 7: 2382-2391.
24. Gungorduk K, Ertas IE, Sahbaz A, Ozvural S, Sarica Y, Ozdemir A, Sayhan S, Gokcu M, Yilmaz B, Sanci M, Inan S, Harma M and Yildirim Y. Immunolocalization of ERK1/2 and p-AKT in normal endometrium, endometrial hyperplasia, and early and advanced stage endometrioid endometrial adenocancer and their prognostic significance in malignant group. Eur J Obstet Gynecol Reprod Biol 2014; 179: 147-152.
25. McPhillips F, Mullen P, MacLeod KG, Sewell JM, Monia BP, Cameron DA, Smyth JF and Langdon SP. Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells. Carcinogenesis 2006; 27: 729-739.
26. Leontovich AA, Zhang S, Quatraro C, Iankov I, Veroux PF, Gambino MW, Degnim A, McCubrey J, Ingle J, Galanis E and D'Assoro AB. Raf-1 oncogenic signaling is linked to activation of mes enchymal to epithelial transition pathway in metastatic breast cancer cells. Int J Oncol 2012; 40: 1858-1864.
27. Schulze A, Lehmann K, Jefferies HB, McMahon M and Downward J. Analysis of the transcriptional program induced by Raf in epithelial cells. Genes Dev 2001; 15: 981-994.
28. Lefloch R, Pouyssegur J and Lenormand P. Single and combined silencing of ERK1 and ERK2 reveals their positive contribution to growth signaling depending on their expression levels. Mol Cell Biol 2008; 28: 511-527.
29. Das G, Shiras A, Shanmuganandam K and Shastry P. Rictor regulates MMP-9 activity and invasion through Raf-1-MEK-ERK signaling pathway in glioma cells. Mol Carcinog 2011; 50: 412-423.
30. Chadha KS, Khoury T, Yu J, Black JD, Gibbs JF, Kuvshinoff BW, Tan D, Brattain MG and Javle MM. Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol 2006; 13: 933-939.